奥沙利铂联合替吉奥与顺铂联合5-氟尿嘧啶方案在食管胃结合部腺癌辅助化疗中的疗效评价.pdf

• 364 • 安 徽 医 药 Anhui Medical and Pharmaceutical Journal 2017 Feb,21(2) 奥沙利铂联合替吉奥与顺铂联合5-氟尿嘧啶方案 在食管胃结合部腺癌辅助化疗中的疗效评价 王琴1，周俊平2，桂东2，董超2，张东成2，唐亮2 (1.皖南医学院，安 徽 芜 湖 241000 ;2.解放军第105医院肿瘤科，安 徽 合 肥 230031) 摘要：目的比较奥沙利铂联合替吉奥（S O X )与顺铂联合5-氟尿嘧啶（P F )方案治疗食管胃结合部腺癌根治术后病人的疗效、 安全性及生活质量。方法食管胃结合部腺癌根治术后病理分期为M 期的病人人选试验，按随机数字表法分为两组，分别接 受S O X 方案或P F 方案化疗，共人组82例，观察组38例,对照组44例，主要评价指标为病人的无病生存期（D F S )、总生存期 (0S )、不良反应及生活质量。结 果 S O X 方案组与P F 方案组的中位D F S 分别为29. 3个月和18.4个月 （P 0. 05),中位0S 分别为35.9个月和24.8个月（P 0.05)。两组毒副反应主要是血液系统异常，以 I ~ n 度为主,差异无统计学意义 。SOX 方案组外周神经系统毒性发生率较P F 方案组高(P 0.05),但均在可耐受范围内;且生活质量的改善明显高于P F 组，差异有 统计学意义(P 〇. 05)。结 论 S O X 作为食管胃结合部腺癌根治术后辅助化疗方案，同P F 方案相比，病人的中位D F S 及0S 均延长，毒副反应均可耐受，给药方便，生活质量改善明显，具有明显的优势。 关键词:食管胃结合部腺癌;辅助化疗;奥沙利铂联合替吉奥方案;顺铂联合5-氟尿嘧啶方案 doi ：10. 3969/j. issn. 1009 - 6469. 2017.02.047 Comparison of efficacy and safety between SOX regimen and PF regimen as adjuvant chemotherapy for adenocarcinoma of esophagogastric junction W A N G Qin1，Z H O U Junping2 ,GUI D o n g 2 , D O N G Chao2 ，Z H A N G Dongcheng2 , T A N G Liang 2 (1. Wannan Medical College ,Wuhu , Anhui 241000, China ； 2. Department of Medical Oncology ,PLA 105 th Hospital , Hefei , Anhui 230031, China) Abstract Objective ： To evaluate the efficacy, toxicity and quality of life of S-l plus oxaliplatin( SOX) versus 5-FU plus cisplatin( PF) as adjuvant chemotherapy for adenocarcinoma of esophagogastric junction( AEG) . Methods Patients with AEG who had accepted radi­ cal operation and the pathological stage which was IH stage were eligible for inclusion. Patients were randomly assigned to receive SOX regimen or PF regimen. Eighty-two patients with AEG who had accepted radical operations were enrolled. 38 patients were in the experi­ mental group and 44 pati